The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

The once-daily, oral dopamine D2/D3 receptor partial agonist has proved to be one of the star assets to emerge from AbbVie's $63 billion mega-merger with Allergan, which originally partnered ...

The dopamine D2/D3 receptor partial agonist has proved to be one of the star assets to emerge from AbbVie's $63 billion mega-merger with Allergan which closed in 2020. Already established as an ...

AbbVie and Richter teamed up to research, develop and commercialize dopamine receptor modulators in 2022. A little more than two years later, AbbVie began a phase 2 trial of the D3 dopamine ...

There are two types of vitamin D supplements available for over-the-counter purchase (vitamin D2 and vitamin D3). Vitamin D3 is the type that most experts believe should be utilized in clinical ...